Alnylam Pharmaceuticals (BSP:A1LN34) Days Sales Outstanding : 68.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Days Sales Outstanding?

Alnylam Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was R$1,607 Mil. Alnylam Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was R$2,155 Mil. Hence, Alnylam Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 68.05.

The historical rank and industry rank for Alnylam Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

BSP:A1LN34' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.3 Med: 96.59 Max: 214.2
Current: 53.15

During the past 13 years, Alnylam Pharmaceuticals's highest Days Sales Outstanding was 214.20. The lowest was 51.30. And the median was 96.59.

BSP:A1LN34's Days Sales Outstanding is ranked better than
66.22% of 891 companies
in the Biotechnology industry
Industry Median: 71.97 vs BSP:A1LN34: 53.15

Alnylam Pharmaceuticals's Days Sales Outstanding increased from Dec. 2022 (57.52) to Dec. 2023 (68.05).

Alnylam Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Alnylam Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Days Sales Outstanding Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

50.46

50.63

63.06

79.52

58.15

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															57.52	65.60	65.29	32.97	68.05

Competitive Comparison of Alnylam Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Days Sales Outstanding falls into.

Alnylam Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Alnylam Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1248.211	+	1606.091)	/	2 )	/	8958.265	*	365
=	1427.151					/	8958.265	*	365
=	58.15

Alnylam Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1607.275	+	1606.091)	/	2 )	/	2154.53	*	365 / 4
=	1606.683					/	2154.53	*	365 / 4
=	68.05

Alnylam Pharmaceuticals (BSP:A1LN34) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Alnylam Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines